News >

Daratumumab Becomes Treatment Staple in Newly Diagnosed Multiple Myeloma

Caroline Seymour
Published: Friday, Feb 14, 2020

Manisha Bhutani, MD, a hematologist at Levine Cancer Institute, Atrium Health

Manisha Bhutani, MD

The foremost choice in the treatment of patients with newly diagnosed multiple myeloma is determining whether a patient is eligible for transplant, as that choice will set the stage for all future decisions.

In the absence of global consensus guidelines, transplant eligibility criteria have become rooted in a patient’s biologic age, frailty, performance status, comorbidities, psychosocial situation, and individual preference, said Manisha Bhutani, MD, in a presentation during the 2020 OncLive® State of the Science Summit™ on Multiple Myeloma.

At the meeting, Bhutani, a hematologist at Levine Cancer Institute, Atrium Health, discussed the differences in treatment for patients with transplant-eligible and -ineligible newly diagnosed multiple myeloma.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication